Adial Pharmaceuticals Inc (NASDAQ: ADIL) has been awarded a key patent combining the use of the company's proprietary genetic diagnostic to detect select genotypes for genetically targeted treatment of alcohol use disorder (AUD) and opioid use disorder (OUD) with the company's lead investigational product AD04. AD04 is a genetically targeted, serotonin-3 receptor antagonist therapeutic agent for Alcohol Use Disorder in heavy drinking patients. "This patent marks another important milestone in ou
Kathmandu: In a major setback, Nepal has banned import of medicines from 16 Indian pharmaceutical companies including IPCA Laboratories, Cadila Healthcare, Baba Ramdev promoted Divya Pharmacy for.